2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3945 Myeloid derived suppressor cells in the myeloma tumor microenvironment and its effect on immunotherapy and CART therapy

Ada Lau, Xiaohong Zhao, MD, PhD2, Mark B. Meads, PhD3, Federico Mazzon, MD4, Pompom Ghosh, PhD5, Ciara Louise L Freeman, MD, PhD6, Doris K. Hansen, MD7, Kinga M. Cid8, chaomei Zhang9, Bailey J. Spence10, Daniel Deavila, MS11, Samer S. Sansil12, Sean Yoder13, Ariel F. Grajales-Cruz, MD14, Omar Alexis Castaneda Puglianini, MD15, Brandon Blue, MD16, Praneeth Reddy Sudalagunta, PhD17, Melissa Alsina, MD18, Rachid Baz, MD19, Ariosto Siqueira Silva, PhD20, Fabiana Perna, MD, PhD21, Paulo Rodriguez, PhD22, Xiaofei Song, PhD23, Kenneth H. Shain, MD, PhD24
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Moffitt Cancer Center, Tampa, Florida, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
24 Moffitt Cancer Center, Tampa, Florida, United States
Multiple myeloma (MM) is a bone marrow resident cancer characterized by an immunosuppressive tumor microenvironment (TME). Accordingly, the TME has a significant bearing on outcomes of targeted immunotherapies such as Daratumumab (Dara), BCMA-targeting chimeric antigen receptor T cell (CART), and T cell engager therapy. Myeloid derived suppressor cells (MDSCs) are key players in dampening the immune response. Improved understanding of MDSC biology and dynamics in the setting of immunotherapy may improve rationale combination therapy. Here, we propose to identify MDSCs and investigate the activity of this key immune population.

Single-cell RNA analyses were performed on two independent cohorts to compare the immunosuppressive TME from patients who received either Dara or BCMA-CART therapy alone. After quality control filtering the Dara treatment cohort, 23 BM samples were obtained from 10 newly diagnosed patients and a total of 76,799 cells were present. Samples from the Dara cohort contained time points ranging from day 0, day 60, and relapse, from responding samples (R) and non-responding samples (NR). In the CART therapy cohort, 32 samples were obtained from 13 relapsed/refractory patients, and a total of 89,155 cells were present.  Samples from the CART cohort contained time points ranging from day 0, day 90, and relapse, >VGPR were classified as responders (R) and <PR were classified as non-responders (NR).

To identify MDSCs, we checked the marker genes on myeloid cell clusters: MHCII (HLA-DR) -, ITGAM (CD14)+, S100A8+, and S100A9+. Further, we identified two subgroups of MDSCs: monocytic MDSCs (mMDSC: gene signature of CD14+, CD274 (PDL1)+, and CD84+) and polymorphonuclear MDSCs (PMN MDSC: gene signature of ARG1+, CEACAM8 (CD66b)+, FUT4 (CD15)+, OLR1 (LOX1)+, and SLC27A2 (FATP2)+).

In the Dara cohort, PMN MDSCs were defined by expression of CD66b and LOX1, whereas an atypical mMDSC-like population was characterized by an MHC II- ARG1+ CD14- phenotype. Gene set enrichment analysis (GSEA) revealed that MDSCs from baseline NR samples were enriched for reactive oxygen species (ROS) and TGF-β signaling pathways, consistent with a more immunosuppressive tumor microenvironment in Dara NR than in R. Cellular interaction analysis revealed that the mMDSCs were communicating with CD8+ T cells through MHC-I pathway ligands, with stronger interactions in the NR samples, suggesting cytotoxic response may be hijacked by MDSCs. Additionally, to evaluate the treatment effects, we compared post- and pre-treatment samples. MDSC-CD8+ T cell crosstalk was reduced after treatment in R but increased in NR. Analysis of curated T cell functional pathways further revealed that, following treatment, CD8+ T cells from R adopted a more immune-activated and cytotoxic phenotype, characterized by enhanced CD40LG-TXNIP and CD172α-MERTK signaling, compared with their pre-treatment state. In contrast, CD8+ T cells from NR exhibited increased exhaustion and chronic dysfunction after treatment, with enrichment of TIMD4-TIM3 and HLA-associated signaling pathways relative to their pre-treatment cytotoxic and inflammatory phenotype.

In the CART cohort, mMDSCs and PMN MDSCs were identified and displayed characteristic genes for arginase 1, ROS, and interferon-stimulated genes. GSEA also revealed that MDSCs from baseline R samples were enriched for ROS, TGF-β, and TNF-α signaling pathways, whereas MDSCs from baseline NR samples exhibited enrichment of IFN-α signaling, indicating a distinct transcriptional program in the RRMM CAR-T cohort compared with the NDMM Dara cohort. Despite these transcriptional differences, cell-cell communication analysis revealed a consistent pattern across both cohorts: MDSC-CD8+ T-cell interactions were elevated in baseline NR, decreased following treatment in R, but increased after treatment in NR. Collectively, these findings suggest that MDSCs promote CD8+ T-cell dysfunction and exhaustion, thereby sustaining an immunosuppressive tumor microenvironment associated with poor therapeutic response.

Our study provides a comprehensive scRNAseq characterization of MDSCs across NDMM & RRMM treated with CD38 and BCMA-targeting immunotherapies. We identified both shared and therapy-specific immunosuppressive programs of MDSCs. These findings provide new insights into the evolution of MDSC biology during disease progression and suggest that targeting MDSCs may enhance the efficacy of both anti-CD38 antibody and BCMA CAR-T therapies. 
Kenneth H. Shain, MD, PhD: Adaptive - Honoraria; AbbVie Inc. - Honoraria; Kite - Honoraria; Bristol Myers Squibb - Honoraria; Regeneron - Honoraria; Sebia - Honoraria; Takeda - Honoraria; Sanofi - Honoraria; Amgen - Honoraria; Arcellx - Honoraria; GSK - Honoraria; Janssen - Honoraria; Karyopharm Therapeutics - Research Funding; Pfizer - Research Funding; AbbVie Inc. - Research Funding